Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin.
Gc-globulin has been found in bronchoalveolar lavage fluid in patients with chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS) and has been shown to enhance neutrophil chemotaxis to C5-derived peptides in vitro. We proposed that Gc-globulin may enhance the inflammatory response in lungs by influencing monocyte chemotaxis to C5-derived peptides as it does with neutrophils. Monocyte chemotaxis was measured in blind well chambers by a leading-front technique. Purified human Gc-globulin had no intrinsic chemotactic activity for monocytes at concentrations ranging from 1 fM to 1 microM. However, Gc-globulin, at concentrations as low as 10 pM, increased monocyte chemotaxis over 10-fold in a concentration-dependent fashion when added to non-chemotactic doses of C5a (0.1 nM) and C5a des Arg (0.5 nM). The chemotaxis-enhancing effect of Gc-globulin was specific for C5-derived peptides, as Gc-globulin did not enhance monocyte chemotaxis to other chemoattractants such as leukotriene B4 or formyl-Met-Leu-Phe. The enhancement of monocyte chemotaxis to C5-derived peptides by Gc-globulin was not a nonspecific effect of anionic proteins, as other serum proteins of similar size and charge did not enhance monocyte chemotaxis to C5a des Arg. These results indicate that Gc-globulin enhances the monocyte response to C5-derived peptides and, together with previous work, indicates that its presence in the airways of patients with COPD and ARDS may up-regulate the monocyte inflammatory response in the lungs.
Piquette
C A
CA
Department of Internal Medicine, St. Louis University School of Medicine, Missouri.
Robinson-Hill
R
R
Webster
R O
RO
D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000378:metabolism / Q000494:pharmacology*; D002633:Chemotaxis / Q000502:physiology*; D015936:Complement C5a / Q000494:pharmacology*; D015937:Complement C5a, des-Arginine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007975:Leukotriene B4 / Q000494:pharmacology; D008173:Lung Diseases, Obstructive / Q000503:physiopathology; D009000:Monocytes / Q000166:cytology* / Q000502:physiology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D012128:Respiratory Distress Syndrome / Q000503:physiopathology; D014809:Vitamin D-Binding Protein / Q000276:immunology / Q000494:pharmacology* / Q000502:physiology
D000906:Antibodies; D002630:Chemotactic Factors; D015937:Complement C5a, des-Arginine; D014809:Vitamin D-Binding Protein; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a